Recent studies on retatrutide, a dual agonist for GLP-1 and GIP, suggest encouraging outcomes in addressing weight gain and type 2 diabetes. Initial evidence from clinical experiments point to substantial decreases in body weight and enhanced glucose control. Further exploration is centered on long-term safety and effectiveness, as well as anticipa